Cargando…

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

BACKGROUND: The prognostic value of the neutrophil-to-lymphocyte ratio (NLR) with large cell neuroendocrine carcinoma (LCNEC) patients remains unclear. Thus, we performed a retrospective study to examine the relationship between the pretreatment NLR and clinical outcome in advanced LCNEC patients an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirasawa, Masayuki, Yoshida, Tatsuya, Horinouchi, Hidehito, Kitano, Shigehisa, Arakawa, Sayaka, Matsumoto, Yuji, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Kanda, Shintaro, Watanabe, Reiko, Yamamoto, Noboru, Watanabe, Shun-ichi, Ohe, Yuichiro, Motoi, Noriko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921668/ https://www.ncbi.nlm.nih.gov/pubmed/33250511 http://dx.doi.org/10.1038/s41416-020-01188-7

Ejemplares similares

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Morita, Chie, et al.
Publicado: (2021)

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
por: Shibaki, Ryota, et al.
Publicado: (2019)

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy
por: Tanaka, Tomohiro, et al.
Publicado: (2023)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations
por: Shinno, Yuki, et al.
Publicado: (2018)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
por: Jo, Hitomi, et al.
Publicado: (2023)

Mixed response to osimertinib and the beneficial effects of additional local therapy
por: Shinno, Yuki, et al.
Publicado: (2019)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
por: Tanaka, Midori, et al.
Publicado: (2018)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody
por: Murakami, Shuji, et al.
Publicado: (2020)

Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
por: Araki, Taisuke, et al.
Publicado: (2023)

CD20(+) tumor‐infiltrating immune cells and CD204(+) M2 macrophages are associated with prognosis in thymic carcinoma
por: Sato, Jun, et al.
Publicado: (2020)

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma
por: Nishimatsu, Kanako, et al.
Publicado: (2023)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
por: Higashiyama, Ryoko Inaba, et al.
Publicado: (2022)

Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study
por: Nakamura, Tomoaki, et al.
Publicado: (2023)

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
por: Seki, Yoshitaka, et al.
Publicado: (2018)

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
por: Tamura, Yosuke, et al.
Publicado: (2015)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
por: Inaba‐Higashiyama, Ryoko, et al.
Publicado: (2020)

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases
por: Tamura, K., et al.
Publicado: (2023)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
por: Katsuya, Yuki, et al.
Publicado: (2023)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
por: Kimbara, Shiro, et al.
Publicado: (2018)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
por: Horinouchi, Hidehito, et al.
Publicado: (2018)

The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
por: Shinno, Yuki, et al.
Publicado: (2020)

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world
por: Kaku, Sawako, et al.
Publicado: (2022)

Correction to: Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world
por: Kaku, Sawako, et al.
Publicado: (2022)

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy
por: Noda‐Narita, Shoko, et al.
Publicado: (2022)

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease
por: Udagawa, Chihiro, et al.
Publicado: (2019)

Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer
por: Aokage, Keiju, et al.
Publicado: (2022)

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
por: Horinouchi, Hidehito, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ofu91hkb1kn1qoiq5b9alp4nfg